Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Current Assets (2016 - 2025)

Abeona Therapeutics has reported Current Assets over the past 15 years, most recently at $204.9 million for Q4 2025.

  • Quarterly results put Current Assets at $204.9 million for Q4 2025, up 103.17% from a year ago — trailing twelve months through Dec 2025 was $204.9 million (up 103.17% YoY), and the annual figure for FY2025 was $204.9 million, up 103.17%.
  • Current Assets for Q4 2025 was $204.9 million at Abeona Therapeutics, down from $216.1 million in the prior quarter.
  • Over the last five years, Current Assets for ABEO hit a ceiling of $232.3 million in Q2 2025 and a floor of $25.5 million in Q3 2022.
  • Median Current Assets over the past 5 years was $67.3 million (2021), compared with a mean of $89.4 million.
  • Biggest five-year swings in Current Assets: crashed 62.45% in 2022 and later soared 185.9% in 2024.
  • Abeona Therapeutics' Current Assets stood at $56.3 million in 2021, then decreased by 5.67% to $53.1 million in 2022, then increased by 4.97% to $55.7 million in 2023, then surged by 80.94% to $100.9 million in 2024, then soared by 103.17% to $204.9 million in 2025.
  • The last three reported values for Current Assets were $204.9 million (Q4 2025), $216.1 million (Q3 2025), and $232.3 million (Q2 2025) per Business Quant data.